After a thorough selection process, ENETS Advisory Board has approved several research initiatives addressing so far unmet medical needs. ENETS is supporting the following trials, which are still recruiting.
The ongoing trial (SEQTOR) is currently investigating the antiproliferative efficacy and safety of everolimus, followed by STZ/5‐FU in advanced pancreatic NET (pNET) in a crossover design upon progression
Important notice: Our privacy policy has been updated. Please click on the link in order to read our current privacy policy including information about the collection and use of data, with a special focus on the use of Google analytics, by ENETS.